Literature DB >> 8208555

Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder.

A J Keen1, M A Knowles.   

Abstract

Loss of heterozygosity (LOH) at loci on chromosome 9 can be detected in more than 50% of bladder tumours, suggesting the presence on this chromosome of one or more suppressor genes for bladder carcinogenesis. Localisation of the target gene(s) by deletion mapping has previously proved difficult due to the uneven distribution of polymorphic loci and the finding of LOH at all these loci in the majority of tumours. We have used a panel of 22 highly informative microsatellite markers, evenly distributed along chromosome 9 to analyse LOH in 95 cases of primary transitional cell carcinoma of the bladder. Forty nine tumours (53%) showed LOH at one or more loci. Of these, 30 had LOH at all informative loci, indicating probable monosomy 9. Nineteen tumours (22%) had subchromosomal deletions, 5 of 9p only, 9 of 9q only and 5 of both 9p and 9q with a clear region of retention of heterozygosity between. The patterns of LOH in these tumours indicated a common region of deletion on 9p between D9S126 (9p21) and IFNA (9p21). A single tumour showed a second site of deletion on 9p telomeric to IFNA indicating the possible existence of 2 target genes on 9p. All deletions of 9q were large, with a common region of deletion between D9S15 (9q13-q21.1) and D9S60 (9q33-q34.1). These results indicate a much higher frequency of subchromosomal deletion than has previously been detected and provide evidence for the simultaneous involvement of distinct suppressor loci on 9p and 9q in bladder carcinoma.

Entities:  

Mesh:

Year:  1994        PMID: 8208555

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  18 in total

Review 1.  Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC).

Authors:  Courtney Pollard; Steven C Smith; Dan Theodorescu
Journal:  Expert Rev Mol Med       Date:  2010-03-25       Impact factor: 5.600

2.  Upregulated MT1-MMP/TIMP-2 axis in the TSU-Pr1-B1/B2 model of metastatic progression in transitional cell carcinoma of the bladder.

Authors:  Christine L Chaffer; Bonnie Dopheide; Daniel R McCulloch; Allan B Lee; Jane M Moseley; Erik W Thompson; Elizabeth D Williams
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

Review 3.  Genetics of bladder cancer.

Authors:  K K Saran; D Gould; C J Godec; R S Verma
Journal:  J Mol Med (Berl)       Date:  1996-08       Impact factor: 4.599

Review 4.  Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression.

Authors:  David J McConkey; Sangkyou Lee; Woonyoung Choi; Mai Tran; Tadeusz Majewski; Sooyong Lee; Arlene Siefker-Radtke; Colin Dinney; Bogdan Czerniak
Journal:  Urol Oncol       Date:  2010 Jul-Aug       Impact factor: 3.498

5.  Measurement of relative copy number of CDKN2A/ARF and CDKN2B in bladder cancer by real-time quantitative PCR and multiplex ligation-dependent probe amplification.

Authors:  Joanne S Aveyard; Margaret A Knowles
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

6.  Loss of heterozygosity of microsatellite loci on chromosome 9p in astrocytic tumors and its prognostic implications.

Authors:  M Maruno; T Yoshimine; A K Muhammad; K Tokiyoshi; T Hayakawa
Journal:  J Neurooncol       Date:  1996-10       Impact factor: 4.130

Review 7.  Molecular pathways in bladder cancer.

Authors:  Stephen G Williams; John P Stein
Journal:  Urol Res       Date:  2004-11-13

Review 8.  Molecular pathogenesis of bladder cancer.

Authors:  Margaret A Knowles
Journal:  Int J Clin Oncol       Date:  2008-08-15       Impact factor: 3.402

9.  Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior.

Authors:  Shyama Majumdar; Edward M Gong; Dolores Di Vizio; Jonathan Dreyfuss; David J Degraff; Martin H Hager; Peter J Park; Joaquim Bellmunt; Robert J Matusik; Jonathan E Rosenberg; Rosalyn M Adam
Journal:  Neoplasia       Date:  2013-07       Impact factor: 5.715

10.  Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder?

Authors:  J M Bartlett; A D Watters; S A Ballantyne; J J Going; K M Grigor; T G Cooke
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.